Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $4.32 per share versus the Zacks Consensus Estimate of a loss of $3.8. This compares to a loss of $3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.68%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $4.21 per share when it actually produced a loss of $2.77, delivering a surprise of +34.2%.Over the last four quarters, th ...